HD researchers from the University College London and Cardiff University evaluated patients’ cognitive and movement symptoms from known study cohort databases. Their results identified an association between the MSH3 gene and disease progression. More specifically, meta-analysis of the TRACK-HD study database revealed this gene to be an indicator of disease burden. This newfound knowledge strengthens the case for considering the MSH3 gene as a possible indicator for HD, as well as making it a potential future therapeutic target for HD treatment.